The objective response rate was 30.5%, and the most common treatment-related adverse events (any grade/grade ≥3) included diarrhea (50.5/1.0%), rash (16.2/1.9%), anemia (10.5/0%), decreased appetite (9.6/1%), and increased alanine transaminase (9.6/3.8%), indicating that both efficacy and tolerability were superior to those of conventional HER2-TKIs [13]. The gene discussed is ERBB2; the disease is anemia (phenotype).